Valuation: Tactile Systems Technology, Inc.

Capitalization 591M 498M 455M 434M 806M 53.54B 833M 5.28B 2.1B 25.8B 2.22B 2.17B 90.09B P/E ratio 2025 *
33.2x
P/E ratio 2026 * 26.5x
Enterprise value 591M 498M 455M 434M 806M 53.54B 833M 5.28B 2.1B 25.8B 2.22B 2.17B 90.09B EV / Sales 2025 *
1.85x
EV / Sales 2026 * 1.7x
Free-Float
98.05%
Yield 2025 *
-
Yield 2026 * -
1 day-4.20%
1 week-2.76%
Current month-8.32%
1 month-11.42%
3 months+7.60%
6 months+110.50%
Current year-8.76%
1 week 26.08
Extreme 26.08
28.13
1 month 26.08
Extreme 26.08
31.38
Current year 26.08
Extreme 26.08
31.38
1 year 8.61
Extreme 8.6098
31.38
3 years 8.61
Extreme 8.6098
31.38
5 years 6.28
Extreme 6.28
63.84
10 years 6.28
Extreme 6.28
76.63
Manager TitleAgeSince
Chief Executive Officer 60 2024-06-30
Director of Finance/CFO 51 2023-03-19
Chief Operating Officer - 2021-10-31
Director TitleAgeSince
Chairman 66 2015-08-31
Director/Board Member 67 2017-09-19
Director/Board Member 60 2020-12-31
Change 5d. change 1-year change 3-years change Capi.($)
-4.20%-2.76%+57.31%+118.32% 591M
+0.14%-0.96%+26.83%+28.02% 13.27B
-1.54%-1.75%-25.93%-19.28% 7.14B
+0.65%-2.48%-5.49%-16.56% 6.02B
-1.05%-2.30%+8.95%+27.69% 5.58B
-1.79%+3.61%-6.75%+40.44% 4.84B
-0.91%+2.73%+1.29%+15.30% 4.57B
+0.03%-2.20%+13.57%-56.28% 1.69B
-0.22%+0.32%+10.89%+15.88% 1.47B
+6.75%+8.28%+2.20%-11.20% 1.22B
Average -0.21%-0.77%+8.28%+14.23% 4.64B
Weighted average by Cap. -0.40%-0.70%+5.10%+11.63%

Financials

2025 *2026 *
Net sales 320M 269M 246M 235M 436M 28.97B 451M 2.86B 1.14B 13.96B 1.2B 1.17B 48.74B 348M 293M 268M 255M 474M 31.52B 491M 3.11B 1.24B 15.19B 1.3B 1.28B 53.04B
Net income 18.36M 15.47M 14.12M 13.48M 25.03M 1.66B 25.88M 164M 65.22M 801M 68.85M 67.44M 2.8B 22.65M 19.08M 17.42M 16.63M 30.87M 2.05B 31.93M 202M 80.45M 988M 84.93M 83.19M 3.45B
Net Debt - -
Logo Tactile Systems Technology, Inc.
Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company providing therapies for people with chronic disorders. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. The Company markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. The Company's Entre system is a basic pneumatic compression device. Kylee, its free mobile application, helps patients learn about lymphedema.
Employees
1,037
Date Price Change Volume
26-02-12 26.46 $ -4.20% 255,065
26-02-11 27.62 $ -0.18% 323,812
26-02-10 27.67 $ +1.36% 205,864
26-02-09 27.30 $ -2.19% 164,813
26-02-06 27.91 $ +2.57% 256,003
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
26.46USD
Average target price
29.75USD
Spread / Average Target
+12.43%

Quarterly revenue - Rate of surprise